Results 241 to 250 of about 60,617 (307)

Identification and functional validation of a novel disease‐causing variant in the noncoding region of NYX

Acta Ophthalmologica, EarlyView.
Abstract Purpose Inherited retinal diseases (IRDs) are a clinically and genetically heterogeneous group of disorders, with ~30% of cases remaining genetically unsolved. Complete congenital stationary night blindness (cCSNB) is a subtype of IRD, usually associated with reduced visual acuity, nystagmus and high myopia.
Filip Spanic, Christelle Michiels, Julien Navarro, Aline Antonio, Christel Condroyer, Camille Andrieu, Billy Gipsy, Sylvie Berthémy‐Pellet, Mathilde Gallice, Isabelle Audo, Christina Zeitz   +10 more
wiley   +1 more source

Generation of proliferative hESC-derived grape-clustered hepatocyte organoids with multipolar architecture as regenerative counterpart via synergy of YAP and IGF2 pathways. [PDF]

Cell Death Dis
Wu H, Liu S, Chen S, Qin C, Yan W, Cao X, Zhou Y, Duan Y.   +7 more
europepmc   +1 more source

Therapeutic potential of natural products in cancer immunotherapy: Advances and challenges

British Journal of Pharmacology, EarlyView.
This review systematically outlines the mechanisms underlying tumour immunotherapy resistance and elucidates the role of natural products in enhancing therapeutic efficacy as immunomodulatory adjuvants. Abstract Immunotherapy has emerged as a clinically pivotal approach in cancer treatment, but its application remains limited to a small subset of ...
Rao Hu, Kaibin Dai, Zhensheng Lin, Mingfang Ye, Minfeng Chen, Xiaobo Li, Dongmei Zhang   +6 more
wiley   +1 more source

Deficiency of exocyst complex component Exoc5 exacerbates the progression of kidney fibrosis. [PDF]

Exp Mol Med
Lim HJ, Han YK, Noh MR, Park YR, Jang SY, Lipschutz JH, Park KM.   +6 more
europepmc   +1 more source

FXR1‐Directed Alternative Splicing of MK5 Drives Hepatocellular Carcinoma Progression by Activating GSK3β Signaling

Cancer Science, EarlyView.
The RNA‐binding protein FXR1 promotes hepatocellular carcinoma (HCC) progression by driving alternative splicing of MK5 to generate an oncogenic isoform, MK5‐L, which activates the Wnt/β‐catenin pathway. Targeting FXR1 with an antisense oligonucleotide suppresses tumor growth in vivo, revealing a promising therapeutic strategy for HCC.
Yutong Li, Jin Xiang, Bin Cheng, Chenhao Li, Kai Wang, Ni Tang, Luyi Huang   +6 more
wiley   +1 more source

Mesenchymal stem cells differentiate dynamic from static load through variable regulation of the Hippo pathway. [PDF]

J Biomech
Xie Z, Sen B, Nikitina N, Howard S, Styner M, Rubin C, Uzer G, Rubin J.   +7 more
europepmc   +1 more source

MAP17 Enhances Chemoresistance and Tumorigenicity of Glioblastoma‐Initiating Cells via the Canonical NF‐кB Pathway

Cancer Science, EarlyView.
MAP 17 is identified as highly expressed in TMZ‐resistant glioblastoma‐initiating cells (GICs). MAP17 enhances GIC proliferation, TMZ resistance, and tumorigenicity through NF‐κB/RELA‐dependent BCL2 upregulation. ABSTRACT Glioblastoma (GBM) is the most common malignant brain tumor in adults.
Shenshen Dou, You Lee Son, Toru Kondo
wiley   +1 more source

Mitophagy Activation via the YAP/Parkin Pathway Underlies the Neuroprotective Action of Tetramethylpyrazine in Cerebral Ischemia/Reperfusion Injury. [PDF]

Biomolecules
Xu L, Wang M, Feng Y, Wang S, Qian Y, Jiang W, Xu J, Fang Y, Zhang Y, Chu L.   +9 more
europepmc   +1 more source

Macrophage‐Specific Loss of Stearoyl‐CoA Desaturase 1 Promotes Colon Cancer by Enhancing M2 TAM Polarization

Cancer Science, EarlyView.
Macrophage‐specific Scd1 deletion accelerates colon cancer progression by suppressing the Hippo‐YAP pathway, which drives immunosuppressive M2 polarization and induces CD8+ T cell exhaustion. Pharmacological YAP activation with TT‐10 effectively reverses this microenvironment, highlighting a promising target for immunotherapy. ABSTRACT In colon cancer (
Qing You, Jiaqi Du, Ziran Wei, Yandong Liu, Weijun Wang, Wenchao Gao   +5 more
wiley   +1 more source

Restoring osimertinib sensitivity in EGFR-mutant NSCLC: the role of anlotinib in modulating Wnt/β-catenin/YAP pathways. [PDF]

Am J Cancer Res
Jing X, Niu J, Li L, Zhai X, Xu Q, Shi Z, Wang Y, Zhu H, Yu J.   +8 more
europepmc   +1 more source